Related Experiment Video
Updated: Jul 17, 2025

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
Published on: October 10, 2017
Dysregulation of mTOR by tau in Alzheimer's disease
George S Bloom1,2,3, Andrés Norambuena1
1Department of Biology, University of Virginia, Charlottesville, Virginia, USA.
Abstract:
Tau was discovered in the mid 1970's as a microtubule-associated protein that stimulates tubulin polymerization, and subsequently was shown to be expressed primarily in neurons, where it is most concentrated in axons. Interest in tau rose by the late 1980's, when it was shown to be the principal subunit of the neurofibrillary tangles (NFTs) that accumulate in Alzheimer's disease (AD) brain, and achieved new heights by the late 1990's, when numerous tau mutations were found to be highly penetrant for AD-related disorders that also are associated with NFTs and came to be known as non-Alzheimer's tauopathies. The role of tau in neurodegeneration is far more complex than whatever effects on neurons may be caused by NFTs, however, and here we review our work on dysregulation of mTOR by tau in AD. mTOR is a protein kinase and master regulator of myriad aspects of cellular behavior. We have defined a complex signaling network whereby aberrant tau phosphorylation provoked by amyloid-β oligomers (AβOs), the building blocks of the amyloid plaques that form in AD brain, cause post-mitotic neurons to re-enter the cell cycle, but to die eventually instead of dividing, which may account for most neuron death in AD. Remarkably, we found that this same neuronal signaling network also poisons a fundamental cell biological process that we discovered, nutrient-induced mitochondrial activation, or NiMA. Tau-dependent cell cycle re-entry and NiMA inhibition occur in cultured neurons within a few hours of exposure to AβOs, and thus may represent seminal processes in AD pathogenesis.
Insights
Aberrant tau phosphorylation, triggered by amyloid-β oligomers, causes neurons to re-enter the cell cycle and die, inhibiting nutrient-induced mitochondrial activation in Alzheimer's disease (AD). This tau-driven neurodegeneration impacts key cellular processes.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Tau protein is primarily found in neurons and is a key component of neurofibrillary tangles (NFTs) in Alzheimer's disease (AD).
- Dysregulation of the mTOR pathway is implicated in various cellular processes and diseases.
- Amyloid-β oligomers (AβOs) are known contributors to AD pathogenesis.
Purpose of the Study:
- To investigate the role of tau in the dysregulation of mTOR signaling in Alzheimer's disease.
- To elucidate the complex mechanisms of tau-induced neurodegeneration beyond NFTs.
- To explore the impact of tau on nutrient-induced mitochondrial activation (NiMA).
Main Methods:
- Review of existing research on tau, mTOR, and AD.
- Analysis of signaling networks involving tau phosphorylation and mTOR.
- Experimental studies on cultured neurons exposed to AβOs.
Main Results:
- Aberrant tau phosphorylation, induced by AβOs, triggers post-mitotic neurons to re-enter the cell cycle, leading to eventual cell death.
- This tau-mediated signaling network inhibits nutrient-induced mitochondrial activation (NiMA).
- Tau-dependent cell cycle re-entry and NiMA inhibition occur rapidly (within hours) upon AβO exposure in neurons.
Conclusions:
- Tau plays a critical role in AD pathogenesis by dysregulating mTOR signaling, leading to neurodegeneration.
- The findings suggest that tau-induced cell cycle re-entry and NiMA inhibition are early and fundamental events in AD.
- Understanding these tau-driven mechanisms offers potential new therapeutic targets for Alzheimer's disease.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Neural Regulation
Alzheimer's Disease: Treatment

